Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib and Chemotherapy in ALK+ NSCLC
NCT05200481Phase 2Active, not recruiting
- Sponsor
- IFCT
- Start
- May 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigatinib in anaplastic lymphoma kinase positive non-small cell lung cancer, sponsored by IFCT. Started May 2022; status: active, not recruiting.
02
Drugs
brigatinib
03
Conditions
anaplastic lymphoma kinase positive non-small cell lung cancer
Beyond the preview
Go deeper on NCT05200481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200481.